Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00367146
Status:
COMPLETED
Last Update Posted:
2011-05-20
First Post:
2006-08-21
Brief Title:
MMF After Pediatric Liver Transplantation
Sponsor:
Hannover Medical School
Organization:
Hannover Medical School
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2007-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The use of CNIs CSA or FK as primary immunosuppressive drugs after pediatric liver transplantation is one of the main causes of chronic kidney disease in these patients in the long term
The study objective is the evaluation of safety of a modification in immunosuppression from a dual-immunosuppression CSA or FK plus steroids to a triple immunosuppression MMF plus CSA reduced dosage plus steroids
The study objective is the evaluation of safety of a modification in immunosuppression from a dual-immunosuppression CSA or FK plus steroids to a triple immunosuppression MMF plus CSA reduced dosage plus steroids
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None